|
1.
|
|
16 p, 1.2 MB |
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab : A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) ;
Bianchi, Luca (U.O.S.D. di Dermatologia Fondazione PTV Policlinico Tor Vergata, Rome, Italy) ;
Khemis, Abdallah (Polyclinique Saint George, Groupe KANTYS, Nice, France) ;
Maul, Julia-Tatjana (University of Zürich) ;
Tsianakas, Athanasios (Fachklinik Bad Bentheim, Bad Bentheim, Germany) ;
Schempp, Christoph M. (University of Freiburg, Germany) ;
Petersen, Kim (LEO Pharma A/S, Ballerup, Denmark) ;
Noergaard, Mia M. (LEO Pharma A/S, Ballerup, Denmark) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians' choice of treatment. [...]
2024 -  10.1007/s13555-023-01092-x
Dermatology and Therapy, Vol. 14 (february 2024) , p. 453-468
|
|
|
2.
|
|
9 p, 267.2 KB |
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis : results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)
/
Reich, Kristian (SCIderm GmbH) ;
Zschocke, I. (SCIderm GmbH) ;
Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ;
de Jong, E.M.G.J. (Radboud University Medical Centre and Radboud University) ;
Gisondi, Paolo (University of Verona) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Warren, R. B. (Manchester Academic Health Science Centre) ;
Ortland, C. (Das Forschungsdock Service for Clinical Development) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Universitat Autònoma de Barcelona
Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. [...]
2017 - 10.1111/bjd.15466
British journal of dermatology, Vol. 177 Núm. 1 (july 2017) , p. 197-205
|
|
|
3.
|
|
7 p, 283.2 KB |
A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features : results from psoriasis patients in Spain
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ;
Reich, Kristian (Sclderm Research Institute and Dermatologikum Hamburg) ;
Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot) ;
Barker, J.N (King's College London) ;
Girolomoni, G. (University of Verona) ;
Paul, C. (Paul Sabatier University and Larrey Hospital) ;
Universitat Autònoma de Barcelona
The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). [...]
2017 - 10.1111/jdv.14195
Journal of the European Academy of Dermatology and Venereology, Vol. 31 Núm. 7 (july 2017) , p. 1176-1182
|
|
|
4.
|
|
9 p, 1013.2 KB |
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis : a post hoc pooled analysis of AMAGINE-2 and -3
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
Iversen, L. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Lambert, Jo (Ghent University) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Kaplan Saday, K. (LEO Pharma A/S) ;
Warren, R. B. (University of Manchester) ;
Universitat Autònoma de Barcelona
Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated. [...]
2022 - 10.1111/jdv.18068
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 8 (august 2022) , p. 1275-1283
|
|
|
5.
|
|
10 p, 1.8 MB |
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
Conrad, Curdin (University Hospital Lausanne CHUV) ;
Kristensen, Lars Erik (Lund University) ;
Smith, Saxon D. (The University of Sydney) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Rich, Phoebe (Oregon Dermatology and Research Center) ;
Sapin, Christophe (Eli Lilly and Company) ;
Holzkaemper, Thorsten (Eli Lilly and Company) ;
Koppelhus, Uffe (Eli Lilly and Company) ;
Schuster, Christopher (Medical University of Vienna) ;
Universitat Autònoma de Barcelona
Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. [...]
2022 - 10.1080/09546634.2021.1892024
Journal of Dermatological Treatment, Vol. 33 Núm. 3 (2022) , p. 1652-1660
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
1 p, 118.3 KB |
Correction to : Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
/
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ;
Langley, Richard G. (Dalhousie University) ;
Paul, Carle (Paul Sabatier University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, Kristian (University Medical Center Hamburg-Eppendorfi) ;
van de Kerkhof, Peter (Radboud University Medical Center) ;
Wu, Hsiuan-Lin (Amgen Inc) ;
Richter, Sven (Amgen Inc) ;
Jardon, Shauna (Amgen Inc) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-021-00656-z
Dermatology and Therapy, Vol. 12 (january 2022) , p. 79
|
|
|
9.
|
|
16 p, 894.7 KB |
Evolution of Patient Perceptions of Psoriatic Disease : Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
/
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ;
Langley, Richard G. (Dalhousie University) ;
Paul, Carle (Paul Sabatier University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
van de Kerkhof, Peter (Radboud University Medical Center) ;
Wu, Hsiuan-Lin (Amgen Inc) ;
Richter, Sven (Amgen Inc) ;
Jardon, Shauna (Amgen Inc) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona
Since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, several systemic treatments for psoriasis (PsO) and/or psoriatic arthritis (PsA) have been approved. The population-based UPLIFT survey was conducted to understand how perceptions of treatment-related outcomes have evolved, particularly for patients with mild to moderate PsO and/or PsA and their dermatologists. [...]
2021 - 10.1007/s13555-021-00635-4
Dermatology and Therapy, october 2021, p. 1-16
|
|
|
10.
|
|
18 p, 504.6 KB |
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure
/
Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ;
Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ;
Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ;
Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ;
Papp, Kim (K Papp Clinical Research and Probity Medical Research) ;
Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ;
Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ;
Renda, Lisa (Eli Lilly and Company) ;
Agada, Noah (Eli Lilly and Company) ;
Xu, Wen (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ;
Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
